Although less studied, APE2 upregulation has been linked to poor prognosis in hepatocellular carcinoma and hematologic cancers, with pan-cancer analyses showing elevated mRNA in kidney, lung, and breast tumors. This evidence concerns the gene APEX2 and hematopoietic and lymphoid cell neoplasm.